Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

ctDNA and bladder cancer: Current understanding and beyond

Insights on the Current Treatment Landscape and Managing Patient Health


    External Content

    Click Play to display this content and agree to third party cookies. (>)

    Update your current cookie settings.

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Urologist James Catto asks oncologist Thomas Powles key questions on the role of ctDNA in the understanding of urothelial cancer and its potential to improve treatment decision-making in the future.


About the experts

Professor Thomas Powles

Thomas Powles, MD, MRCP, MBBS, is a Professor of Genitourinary Oncology and Director of Barts Centre in London, UK. 

Disclosures

  • Consultancy/honorarium: AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono (EMD in US), Astellas, Johnson & Johnson, Eisai, Roche
  • Grant/funding to institution: AstraZeneca, Roche, BMS, Exelixis, Ipsen Merck MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono (EMD in US), Astellas , Johnson & Johnson , Eisai
  • Travel/accommodation: Roche, Pfizer, MSD, AstraZeneca, Ipsen

Professor James Catto

James Catto is NIHR Research Professor, Professor of Urological Surgery at the University of Sheffield and an Honorary Consultant Urological Surgeon at Sheffield Teaching Hospitals NHS Trust.  

Disclosures

  • Consulting fees from AstraZeneca, Ferring, Ipsen, Roche, and Janssen; 
  • Speaker fees from Bristol Myers Squibb, Pfizer, Merck Sharp & Dohme, Janssen, Astellas, Nucleix, and Roche; 
  • Honoraria for membership in advisory boards from Ferring, Roche, Gilead, Photocure, Pfizer, Bristol Myers Squibb, QED Therapeutics, and Janssen; 
  • Research funding from Roche.

Financial disclosure

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Disclaimer

Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Image Credits

Attention: This content is intended for healthcare professionals only

In order to proceed please confirm whether you are a healthcare professional.

No, I am not a
healthcare professional Yes, I am a
healthcare professional